Paradoxical roles of tumor lymphangiogenesis on tumor immunity and implications for immunotherapy - Resubmission 01

NIH RePORTER · NIH · R01 · $370,575 · view on reporter.nih.gov ↗

Abstract

Project Summary In melanoma and other cancers, the expansion of the local lymphatic network via expression of VEGF-C in the tumor microenvironment promotes metastasis and is widely correlated with poor prognosis. We and others have shown that VEGF-C-activated lymphatic vessels play important immune suppressive roles in the tumor microenvironment. Paradoxically, we have observed that in mouse melanoma models, lymphangiogenic tu- mors were more responsive to immunotherapy, including in adoptive T cell therapy, dendritic cell vaccines, and protein vaccination. Here we propose a research program that explores this other side of tumor lymphangio- genesis, and suggest a novel hypothesis that while VEGF-C in the tumor microenvironment can induce in- flammation and immune suppression, it also enhances the infiltration of naïve T cell infiltration, at least in part by upregulating the lymphoid homing chemokine CCL21. This enhanced infiltration, in turn, can prime the tu- mor for enhanced responsiveness to immunotherapy. Three aims are proposed to explore (i) validation and mechanistic underpinnings in mouse models, (ii) relevance to human melanoma, and (iii) translational applica- tion.

Key facts

NIH application ID
10119257
Project number
5R01CA219304-04
Recipient
UNIVERSITY OF CHICAGO
Principal Investigator
Melody Ann Swartz
Activity code
R01
Funding institute
NIH
Fiscal year
2021
Award amount
$370,575
Award type
5
Project period
2018-04-01 → 2023-03-31